are microdomains comprised of about 1000 unique proteins that are interacting with one another via specialized multipotent scaffolding molecule. Postsynaptic density-95 (PSD-95) is a multipotent scaffolding, trafficking, and clustering protein that links glutamate receptors, signaling molecules, and other structural proteins at postsynaptic sites. More than 95% of PSD-95 expression is localized to excitatory synapses, and it is the most abundant scaffolding protein within the postsynaptic density. Mounting genetic, proteomic, and pharmacological evidence converges on alterations in the postsynaptic density of excitatory synapses in subjects with schizophrenia. Cognitive and negative symptoms associated with dysfunction of limbic circuitry, including working memory and motivation, are particularly implicated by this mechanism. To investigate excitatory postsynaptic protein hubs in schizophrenia, we assessed the PSD-95 protein interactome from brain tissue of subjects with schizophrenia and controls. Methods: Human brain tissue from fifteen subjects with schizophrenia and fifteen control subjects from the DLPFC was processed for affinity purification of PSD-95 protein complexes. We confirmed PSD-95 capture and enrichment from each sample using Western blot analyses. Samples were then pooled by region and assessed by mass spectrometry for a quality control step. Pooled samples were run in triplicate. Go versus nogo was based on finding more than 500 unique peptides in each pooled sample from each region. Next, individual samples were run through our mass spectrometry protocol in triplicate. We then subtracted any non-specifically captured peptides identified by our IgG control studies that were performed in parallel to PSD-95 affinity purification. Data were normalized within each of the mass spec runs to the most intense PSD-95 peptide. This PSD-95 peptide used for normalization was the same in every sample. Peptides that were present in at least 2 of 3 technical replicates were carried forward and subjected to quantile normalization. Peptides missing in a technical replicate were replaced by imputation, and the dataset subjected to unsupervised clustering. We also performed a semisupervised clustering protocol, non negative matrix factoring (NMF). Consensus signatures of 200 peptides were identified for each brain region, and subjected to traditional and alternative bioinformatics analyses to identify pathways, processes and compounds associated with the signatures for each brain region. Results: Preliminary analyses indicate changes in the PSD-95 interactome consistent with diminished NMDA receptor signaling complex activity in schizophrenia, with lower levels of NMDA-subtype glutamate receptor subunits, as well as protein kinases associated with postsynaptic signaling in this complex. Specific biological pathways and processes identified include metabolic and inflammatory pathways. We will also present proteomic signatures generated from this dataset, and interrogate the iLINCS perturbagen database to identify drugs and genes that simulate or reverse this signature. Discussion: Our preliminary data suggest that NMDA receptor function is compromised in schizophrenia. Additional work is needed to see if this is an effect of antipsychotic medications. Our proteomic findings extend the NMDA receptor hypothesis beyond the transcriptome, highlighting an important new approach for assessing abnormalities of synapses in postmortem brain.
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Background: In the post-genomic era, proteomics has emerged as a powerful tool to unravel biomarker candidates and to understand human diseases from the molecular point of view. In the last decade, our group mapped the proteome of several post-mortem brain regions and the cerebrospinal fluid from schizophrenia patients and controls to help deciphering schizophrenia's pathobiology. These results led us to more recently focus on subproteomes and protein interaction analysis. Methods: Using ion mobility-enhanced, data-independent acquisitions and 2D-nano UPLC fractionation, we investigated the mitochondrial, nuclear and cytosolic subproteomes of the dentate nucleus and caudate nucleus as well as the protein interactome of potential protein targets to schizophrenia. Results: As previously observed, have found recurrently the differential expression energy associated proteins as well as signaling pathways associated to glutamatergic dysfunction. Proteins associated to translation machinery were also found differentially expressed, implicating spliceosome dysfunction to schizophrenia. In order to understanding this better, we investigated the protein interactome of hnRNPs by co-immunoprecipitation in the disease context. Discussion: Proteomics findings may provide an integrated picture of schizophrenia´s pathobiology and the identification of proteins associated to energy, signalling and translational pathways may trace back the origins of schizophrenia. Background: The identification of early biomarkers of psychotic disorder is important because early treatment is associated with improved outcome. We have previously shown that altered complement and coagulation pathway associated proteins are associated pathway with psychotic disorder at age 18. In the current study we test the hypothesis that altered complement pathway proteins are associated with persisting psychotic experiences from age 11 to age 18. Methods: The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective general population cohort, and a rich resource of demographic, environmental, and clinical data on the individuals involved. We studied a subsample of the cohort who participated in psychiatric assessment interviews at age 11 and 18, and who provided plasma samples at age 11. Semi-targeted proteomic profiling was used to specifically assess the complement pathway proteins in age 11 children who experienced psychotic experiences (but not disorder) at age 11 and age 18 (n=39) compared to age 11 children who only experienced psychotic experiences at age 11. Results: 11 of 34 proteins assessed were significantly differentially expressed at p<0.05 and of these 8 remained significant following correction for multiple comparisons. Protein changes were in keeping with increased proteins expression of most complement pathway proteins. Several protein changes represented specific replications of the changes observed in age 11 samples prior to psychotic disorder at age 18, namely increased plasminogen, complement factor H, and complement factor 1r. Discussion: Our findings implicate the blood complement system in the persistence of psychotic experiences from age 11 to age 18. Considering that psychotic experiences are predictive of many psychiatric disorders our findings implicate the complement system not just in psychotic disorders, but more broadly in the vulnerability to a range of adult psychiatric disorders.
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